Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 45
- Reported
- 38
- Verified
- 33
- Gap
- +12
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Proceed with caution
- Why
- Reassuring safety signal and intriguing female lean-mass/pain effects, but the primary endpoint failed and the dosing/cohort weaknesses make efficacy claims premature.
- Next
- Wait for an adequately powered, sex-balanced trial using commercial-bioavailability rapamycin and a pre-registered primary endpoint before treating any healthspan claim as established; do not infer mortality/disease benefit, which remains unproven in healthy adults.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 0
- Tier 2
- 3
- Tier 3
- 5
- Supports
- 2
- Contradicts
- 4
- Context
- 2
- Latest observed
- 2025-12-11
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.